FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Videos|September 8, 2016
Challenges Facing Independent Specialty Pharmacies
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of the CSI Specialty Group, discusses difficulties for an independent specialty pharmacy in the current landscape.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of the CSI Specialty Group, discusses difficulties for an independent specialty pharmacy in the current landscape.
Advertisement
Related to this article
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5